511 results
The purpose of this study is to monitor whether preicncisional bupivacaine (bupivacaïne 0,5% with epinefrine 1:200.000), infiltration in trocarcincisions reduces postoperative wound pain.
The primary objective of this study is to evaluate the safety and effectiveness of the Genous Bio-engineered R stentTM in conjunction with optimal statin therapy (80mg of atorvastatin), in the treatment of elective patients with up to two de novo…
This study is designed to demonstrate equal therapeutic effect of Myfortic® as compared to MMF in this patient group, thus improving therapeutic efficacy.
Primary objectives:*To evaluate the effects on labour supply (work loss days, work cut back days with lower productivity) and work productivity/functioning of psychiatric outpatient treatment (treatment as usual; TAU) vs. psychiatric outpatient…
To study the presence, number, type and specificity of tumour-specific immune response in the peripheral blood, tumour-draining lymph nodes and the tumour of patients with different types of HNSCC at different time-points during their normal…
To evaluate the efficacy ofa. early intensification of rituximab combined with 2-weekly CHOP+G-CSF (R-CHOP14) in remission induction treatment in comparison to standard R-CHOP14b. maintenance treatment with rituximab in patients in remission after R…
To assess the response rate to the combination of gemcitabin plus oxlaiplatin in 5 different strata of relapsed/refractory pediatric solid tumors, in whom standard treatment has failed. Secondary objectives are the safety, the duration of response,…
1. Is passive movement therapy an effective intervention on the severity of paratonia in comparison with usual care without passive movement therapy?2. Is passive movement therapy an effective intervention for improvement of daily care?
To establish one large overarching cohort including all types of SpA (both non-radiographic, radiographic axial SpA and peripheral SpA) regardless of the disease stage and treatment and to longitudinally asses several disease aspects of SpA. The…
Primary* To compare the efficacy (Major Molecular Response, MMR, rate at 12 months) Secondary* To compare the rate of durable MMR at 24 months in patients with a MMR at 12 months* To compare the rate, time to and duration of complete cytogenetic…
Primary objective· • To investigate the safety and tolerability and establish either the dose of KU-0059436 which causes inhibition of PARP in combination with an active dose of carboplatin or the maximum tolerated dose (MTD) of KU-0059436 in…